Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | KDM1A | O60341 | 7/20 | 0.54 |
| ▸ | MAOA | P21397 | 4/20 | 0.52 |
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776196 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2NPSR1KDM1AMAOAMAOB | |
| SCHEMBL3457343 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2NPSR1KDM1AMAOAMAOB | |
| SCHEMBL6154005 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2NPSR1KDM1AMAOAMAOB | |
| SCHEMBL7980208 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2NPSR1KDM1AMAOAMAOB | |
| SCHEMBL6153775 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2NPSR1KDM1AMAOAMAOB | |
| SCHEMBL18043489 | 0.83 | EPHX2 (0.56) | SMN1; SMN2NPSR1KDM1AMAOAMAOB | |
| SCHEMBL18043490 | 0.83 | EPHX2 (0.56) | SMN1; SMN2NPSR1KDM1AMAOAMAOB | |
| SCHEMBL12972001 | 0.82 | KDM1A (0.71) | SMN1; SMN2NPSR1KDM1AMAOAMAOB | |
| SCHEMBL15091992 | 0.82 | KDM1A (0.71) | SMN1; SMN2NPSR1KDM1AMAOAMAOB | |
| SCHEMBL2362145 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2NPSR1KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389580-B2 | Arylcyclopropylamines and methods of use | DUKE UNIVERSITY (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100324147-A1 | ARYLCYCLOPROPYLAMINES AND METHODS OF USE | DUKE UNIVERSITY | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324147-A1 | ARYLCYCLOPROPYLAMINES AND METHODS OF USE | MAOA, MAOB, PNMT | SMN1; SMN2 2788/4885NPSR1 2678/4885KDM1A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.